ATE212991T1 - Thiazolidinedione- und oxazolidinedione-derivate mit antidiabetischen, hypolipidämischen und anti hypertensiven eigenschaften - Google Patents

Thiazolidinedione- und oxazolidinedione-derivate mit antidiabetischen, hypolipidämischen und anti hypertensiven eigenschaften

Info

Publication number
ATE212991T1
ATE212991T1 AT98915492T AT98915492T ATE212991T1 AT E212991 T1 ATE212991 T1 AT E212991T1 AT 98915492 T AT98915492 T AT 98915492T AT 98915492 T AT98915492 T AT 98915492T AT E212991 T1 ATE212991 T1 AT E212991T1
Authority
AT
Austria
Prior art keywords
pharmaceutically acceptable
antidiabetic
hypolipidemic
thiazolidinedione
derivatives
Prior art date
Application number
AT98915492T
Other languages
German (de)
English (en)
Inventor
Vidya Bhushan Lohray
Braj Bhushan Lohray
Ranga Madhavan Gurram
Foundation
Rajagopalan Ramanujam
Colony
Ranjan Chakrabarti
Original Assignee
Reddy Research Foundation
Reddy Cheminor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/982,962 external-priority patent/US6011036A/en
Application filed by Reddy Research Foundation, Reddy Cheminor Inc filed Critical Reddy Research Foundation
Application granted granted Critical
Publication of ATE212991T1 publication Critical patent/ATE212991T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30Phthalazines
    • C07D237/32Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/021,2-Oxazines; Hydrogenated 1,2-oxazines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT98915492T 1997-12-02 1998-04-10 Thiazolidinedione- und oxazolidinedione-derivate mit antidiabetischen, hypolipidämischen und anti hypertensiven eigenschaften ATE212991T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/982,962 US6011036A (en) 1997-04-15 1997-12-02 Heterocyclic compounds having antidiabetic hypolipidemic antihypertensive properties process for their preparation and pharmaceutical compositions containing them
PCT/US1998/007285 WO1998045292A1 (en) 1997-12-02 1998-04-10 Thiazolidinedione and oxazolidinedione derivatives having antidiabetic, hypolipidaemic and antihypertensive properties

Publications (1)

Publication Number Publication Date
ATE212991T1 true ATE212991T1 (de) 2002-02-15

Family

ID=25529696

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98915492T ATE212991T1 (de) 1997-12-02 1998-04-10 Thiazolidinedione- und oxazolidinedione-derivate mit antidiabetischen, hypolipidämischen und anti hypertensiven eigenschaften

Country Status (6)

Country Link
EP (1) EP0971917B1 (enExample)
JP (1) JP4391597B2 (enExample)
AT (1) ATE212991T1 (enExample)
AU (1) AU6966498A (enExample)
DE (1) DE69803750T2 (enExample)
WO (1) WO1998045292A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19921567A1 (de) * 1999-05-11 2000-11-16 Basf Ag Verwendung von Phthalazine-Derivaten
WO2001066135A1 (en) 2000-03-08 2001-09-13 Novo Nordisk A/S Lowering serum lipids
EP1444219A1 (en) 2001-10-12 2004-08-11 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
EP1458382A1 (en) 2001-12-21 2004-09-22 Novo Nordisk A/S Amide derivatives as gk activators
EP1501822B1 (en) * 2002-04-30 2010-12-15 Kudos Pharmaceuticals Limited Phthalazinone derivatives
CA2488642C (en) 2002-06-27 2011-09-06 Dharma Rao Polisetti Aryl carbonyl derivatives as glucokinase activators
KR20060089874A (ko) 2003-09-30 2006-08-09 노보 노르디스크 에이/에스 신규 멜라노코르틴 수용체 작용제
WO2005056036A2 (en) 2003-12-09 2005-06-23 Novo Nordisk A/S Regulation of food preference using glp-1 agonists
PL1723128T3 (pl) 2004-01-06 2013-04-30 Novo Nordisk As Pochodne heteroarylowe mocznika oraz ich zastosowanie jako aktywatory glukokinazy
JP2007536344A (ja) 2004-05-04 2007-12-13 ノボ ノルディスク アクティーゼルスカブ 新規のインドール誘導体
US8410047B2 (en) 2004-06-11 2013-04-02 Novo Nordisk A/S Counteracting drug-induced obesity using GLP-1 agonists
CN101060856B (zh) 2004-11-22 2011-01-19 诺和诺德公司 可溶、稳定的含胰岛素制剂
JP2008521864A (ja) 2004-12-03 2008-06-26 トランステック・ファーマ、インコーポレイテッド ヘテロ芳香族グルコキナーゼ活性化剤
BRPI0613564A2 (pt) 2005-07-04 2011-01-18 Novo Nordisk As compostos, seus usos na preparação de composições farmacêuticas e composições farmacêuticas compreendendo os mesmos
MX2008000255A (es) 2005-07-14 2008-04-02 Novo Nordisk As Activadores de urea glucocinasa.
ES2426345T3 (es) 2005-07-20 2013-10-22 Eli Lilly And Company Compuesto unidos en posición 1-amino
EP1951658B1 (en) 2005-11-17 2012-09-26 Eli Lilly & Company Glucagon receptor antagonists, preparation and therapeutic uses
KR101280333B1 (ko) 2006-03-28 2013-07-02 하이 포인트 파마슈티칼스, 엘엘씨 히스타민 h3 수용체 활성을 갖는 벤조티아졸
AU2007267197B2 (en) 2006-05-29 2011-12-01 High Point Pharmaceuticals, Llc 3- (1, 3-Benzodioxol-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine H3 receptor antagonist
EP2097388B1 (en) 2006-11-15 2011-09-07 High Point Pharmaceuticals, LLC Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes
US8022066B2 (en) 2006-11-15 2011-09-20 High Point Pharmaceuticals, Llc 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes
JP5226008B2 (ja) 2007-01-11 2013-07-03 ノボ・ノルデイスク・エー/エス ウレアグルコキナーゼアクチベーター
WO2011104378A1 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Peptides for treatment of obesity
BR112012021231A2 (pt) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
BR112012024379A2 (pt) 2010-03-26 2017-01-10 Novo Nordisk As "peptídeos glucagon, seu uso, bem como composição farmacêutica"
EP2670368A4 (en) 2011-02-03 2015-04-15 Pharmedica Ltd NEW ORAL DISSOLUTION FILMS FOR INSULIN DELIVERY FOR THE TREATMENT OF DIABETES
MX2013011175A (es) 2011-03-28 2013-11-01 Novo Nordisk As Analogos de glucagon novedosos.
WO2013041678A1 (en) 2011-09-23 2013-03-28 Novo Nordisk A/S Novel glucagon analogues
RU2683039C2 (ru) 2013-04-18 2019-03-26 Ново Нордиск А/С Стабильные совместные агонисты рецептора глюкагоноподобного пептида-1/глюкагона пролонгированного действия для медицинского применения
JP2017525656A (ja) 2014-06-04 2017-09-07 ノヴォ ノルディスク アー/エス 医療用のglp−1/グルカゴン受容体コアゴニスト
WO2018167194A1 (en) 2017-03-15 2018-09-20 Novo Nordisk A/S Bicyclic compounds capable of binding to melanocortin 4 receptor
US20210221867A1 (en) 2018-05-15 2021-07-22 Novo Nordisk A/S Compounds Capable of Binding to Melanocortin 4 Receptor
WO2020053414A1 (en) 2018-09-14 2020-03-19 Novo Nordisk A/S Bicyclic compounds capable of acting as melanocortin 4 receptor agonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0306228B1 (en) * 1987-09-04 1999-11-17 Beecham Group Plc Substituted thiazolidinedione derivatives
GB8820389D0 (en) * 1988-08-26 1988-09-28 Beecham Group Plc Novel compounds
GB8919417D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
GB9023583D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds
GB9023585D0 (en) * 1990-10-30 1990-12-12 Beecham Group Plc Novel compounds

Also Published As

Publication number Publication date
AU6966498A (en) 1998-10-30
DE69803750T2 (de) 2002-09-12
EP0971917A1 (en) 2000-01-19
EP0971917B1 (en) 2002-02-06
WO1998045292A1 (en) 1998-10-15
JP4391597B2 (ja) 2009-12-24
DE69803750D1 (de) 2002-03-21
JP2002508745A (ja) 2002-03-19

Similar Documents

Publication Publication Date Title
ATE212991T1 (de) Thiazolidinedione- und oxazolidinedione-derivate mit antidiabetischen, hypolipidämischen und anti hypertensiven eigenschaften
IL142649A0 (en) Azole derivatives
CA2258949A1 (en) Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
DK0418845T3 (da) Pyrazolderivater, fremgangsmåder til fremstilling deraf og farmaceutisk præparat omfattende samme
AP2001002066A0 (en) Substituted oxazoles and thiazoles derivatives at hPPAR gamma and hPPAR alpha activators
ES2137169T3 (es) Nuevos derivados de tiazolilbenzofurano, procedimientos para su preparacion y composicion farmaceutica que los contiene.
DE69830504D1 (de) Antithrombotische mitteln
WO1999008501A3 (en) New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
NZ507144A (en) Benzamide derivatives useful for the treatment of diseases mediated by cytokines
PT1140993E (pt) Derivados de glicopeptidos e composicoes farmaceuticas contendo os mesmos
DK0687251T3 (da) 1,3-dihydroindol-2-on-derivater, der er substitueret i 3-stillingen med en nitrogengruppe, til anvendelse som vasopressin- og/eller ocytocin-agonister og/eller -antagonister
DE50005437D1 (en) Substituierte thien-3-yl-sulfonylamino(thio)carbonyl-triazolin(thi)one
PT863136E (pt) Derivados de azetidina e de pirrolidina
WO2002051819A3 (en) Heterocyclic compounds having antibacterial activity, process for their preparation and pharmaceutical compositions containing them
DK0605228T3 (da) Thiazolidindionderivater, deres fremstilling og anvendelse
BR0308145A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
CA2321188A1 (en) Derivatives of azetidine and pyrrolidine
EA200000023A1 (ru) Производные 2-(-4-арил или гетероарил-пиперазин-1-илметил) -1h-индола
DE69824756D1 (de) Substituierte thiazolidinedione und oxazolidinedione mit antidiabetischen,hypolipidämischen und antihypertensiven eigenschaften
KR970707122A (ko) 퀴놀린 유도체(quinoline derivative)
MX9701116A (es) Profarmacos de 5-(2-[4-(1,2-benzoisotiazol-3-il)-1-piperazinil]etil)-6-clor o-1,3-dihidro-2h-indol-2-ona.
DE69827614D1 (de) Chinoxalindionen
BR9915898A (pt) Compostos, composição farmacêutica, e, utilização de um composto
AU653019B2 (en) New urea derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same